Global Prostate Specific Antigen (PSA) Test Market Expected to Achieve 11.8% CAGR by 2029: Growth Forecast Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Prostate Specific Antigen (PSA) Test Market Size By 2025?
The market encompassing prostate specific antigen (psa) testing has experienced swift expansion lately, projected to ascend from a valuation of $4.15 billion in 2024 to $4.65 billion by the following year, reflecting an impressive compound annual growth rate (CAGR) of 11.9%. This historical upward trajectory is fundamentally driven by several key factors, including heightened public and medical cognizance, a growing demographic of older individuals, progress in medical technology, formal clinical guidelines supporting its use, and continuous evolution within the pharmaceutical sector.

How Big Is the Prostate Specific Antigen (PSA) Test Market Size Expected to Grow by 2029?
Anticipating substantial expansion, the market encompassing the prostate specific antigen (psa) test is projected for swift ascent in the forthcoming years, reaching a valuation of $7.27 billion by 2029, underpinned by an 11.8% compound annual growth rate (CAGR); this future growth trajectory is largely fueled by improvements in testing precision, the increasing adoption of personalized medical strategies, and the demographic trend of an aging global populace, while significant market dynamics expected during this period involve a growing inclination towards utilizing biomarker combinations, continuous technological breakthroughs, the deployment of point-of-care testing solutions, the incorporation of digital health technologies, and a stronger emphasis placed on both the early identification and preventative measures related to prostate health.

View the full report here:
https://www.thebusinessresearchcompany.com/report/prostate-specific-antigen-psa-test-global-market-report

Which Key Market Drivers Powering Prostate Specific Antigen (PSA) Test Market Expansion and Growth?
Anticipated escalation in the incidence of prostate carcinoma is projected to fuel the advancement of the market for the prostate-specific antigen (PSA) test moving ahead. This cancer originates within the prostate gland, which is part of both male and female reproductive anatomy, and the routine screening method employed for men involves the PSA test, quantifying the amount of this antigen present in the blood to facilitate early identification and gauging of risk; for illustrative context, data provided by the American Society of Clinical Oncology (ASCO), a professional body for oncology situated in the US, indicated that in 2023 alone, the United States saw an estimated 288,300 new diagnoses of prostate cancer and roughly 34,700 fatalities resulting from the disease, underscoring how the mounting occurrence of prostate cancer serves as a primary catalyst for the expansion of the PSA testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12576&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Prostate Specific Antigen (PSA) Test Market?
A primary driver for the prostate-specific antigen (PSA) test market centers around the rapid adoption of technological innovation. Leading entities within this market space are engaging in the creation of sophisticated screening methodologies intended to secure or enhance their competitive standing. As an illustration, in February of 2023, the American diagnostic firm LynxDx Inc. introduced MyProstateScore 2.0, a urine-based screening method for prostate cancer that does not require invasive procedures. This pioneering test employs a composite assay featuring 18 distinct biomarkers, notably incorporating the newly identified gene fusion T2:ERG, enabling healthcare providers to generate a risk assessment tailored to the individual patient. Furthermore, this diagnostic tool furnishes extremely precise, risk-stratified evaluations, which serve to inform clinical choices for individuals presenting with elevated PSA levels or irregular digital rectal examination (DRE) results, ultimately holding promise for enhancing the efficacy of both prostate cancer detection and subsequent management.

What Are the Emerging Segments in the Prostate Specific Antigen (PSA) Test Market?
The prostate specific antigen (psa) testmarket covered in this report is segmented -

1) By Type: Clinical Laboratory Improvement Amendments (CLIA); Enzyme-Linked Immunosorbent Assay (ELISA); Fluorescence Immunoassay (FIA); Other Types
2) By Application: Screening; Post-Treatment Monitoring; Other Applications
3) By End User: Hospitals; Diagnostic Centers; Research Institutes; Other End Users

Subsegments:
1) By Clinical Laboratory Improvement Amendments (CLIA): CLIA Waived Tests; Non-CLIA Tests
2) By Enzyme-Linked Immunosorbent Assay (ELISA): Sandwich ELISA Kits; Competitive ELISA Kits
3) By Fluorescence Immunoassay (FIA): Point-Of-Care FIA; Laboratory-Based FIA
4) By Other Types: Chemiluminescent Immunoassay (CLIA); Radioimmunoassay (RIA)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12576&type=smp

Who Are the Global Leaders in the Prostate Specific Antigen (PSA) Test Market?
Major companies operating in the prostate specific antigen (PSA) test market include Siemens AG, F. Hoffmann-La Roche AG, Bayer AG, Abbott Laboratories, Becton dic*kinson and Company, PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin SpA, OPKO Health Inc., R&D Systems Inc., Meso Scale Diagnostics LLC, Tosoh America Inc., Fujirebio Europe N.V., Boditech Med Inc., DRG International Inc., BioVision Inc., Enzo Life Sciences Inc., RayBiotech Inc., Novus Biologicals LLC, Creative Diagnostics Inc., Elabscience, LifeSpan BioSciences Inc., American Laboratory Products Company Ltd., Accuquik Inc.

Which are the Top Profitable Regional Markets for the Prostate Specific Antigen (PSA) Test Industry?
North America was the largest region in the prostate specific antigen (PSA) test market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate specific antigen (PSA) test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12576

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.